Rhyner K
Universitätsspital Zürich, Departement für Innere Medizin.
Schweiz Med Wochenschr. 1988 Mar 19;118(11):375-80.
Recombinant human erythropoietin raises serum erythropoietin concentrations to adequate levels and restores the hematocrit to normal values in the vast majority of anemic, end stage renal disease patients undergoing regular hemodialysis. It can eliminate the need for transfusions and thus the risk of immunologic sensitization, infection and iron overload. Erythropoietin not only alters laboratory findings but improves the well being and performance of patients on hemodialysis as well. Side effects are minimal and neither antibodies nor resistance to the recombinant hormone have been observed so far. Along with the rise in hematocrit and blood viscosity some patients developed increased blood pressure and a few hypertensive encephalopathy, but after brief interruption of therapy erythropoietin treatment could be continued in combination with antihypertensive drugs. The pathophysiology of the increase in blood pressure, the risk of encephalopathy and the possibly somewhat higher risk of thrombosis remain to be elucidated. Nevertheless, the first recombinant hematopoietic hormone has passed its first clinical trials with success.
重组人促红细胞生成素可将血清促红细胞生成素浓度提高到适当水平，并使绝大多数接受定期血液透析的终末期肾病贫血患者的血细胞比容恢复到正常水平。它可以消除输血的必要性，从而消除免疫致敏、感染和铁过载的风险。促红细胞生成素不仅改变实验室检查结果，还能改善血液透析患者的健康状况和身体机能。副作用极小，迄今为止尚未观察到针对重组激素的抗体或耐药性。随着血细胞比容和血液粘度的升高，一些患者出现血压升高，少数患者发生高血压脑病，但在短暂中断治疗后，促红细胞生成素治疗可与抗高血压药物联合继续进行。血压升高的病理生理学、脑病风险以及可能略高的血栓形成风险仍有待阐明。尽管如此，第一种重组造血激素已成功通过其首次临床试验。
